Concord Medical Co., Ltd. (TPEX:6518)
Taiwan · Delayed Price · Currency is TWD 31.55
+1.30 (4.30%)
Aug 19, 2026, 1:50 PM CST
Concord Medical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,020 | 873 | 860 | 853 | 787 | 450 | |
Market Cap Growth | 14.39% | 1.55% | 0.78% | 8.48% | 74.81% | 28.57% |
Enterprise Value | 1,000 | 804 | 783 | 779 | 693 | 643 |
Last Close Price | 30.60 | 24.77 | 23.27 | 22.20 | 19.76 | 14.82 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12.01 | 12.96 | 17.35 | 19.96 | 15.53 | 13.08 |
PS Ratio | 0.98 | 0.91 | 0.97 | 1.02 | 0.89 | 0.61 |
PB Ratio | 1.36 | 1.16 | 1.23 | 1.25 | 1.11 | 0.71 |
P/TBV Ratio | 1.45 | 1.24 | 1.24 | 1.26 | 1.18 | 0.71 |
P/FCF Ratio | 7.93 | 7.08 | 11.60 | 34.07 | 6.72 | 3.89 |
P/OCF Ratio | 7.77 | 5.55 | 5.78 | 7.54 | 5.09 | 3.28 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.96 | 0.83 | 0.88 | 0.94 | 0.78 | 0.87 |
EV/EBITDA Ratio | 6.70 | 6.23 | 6.53 | 5.93 | 5.00 | 5.75 |
EV/EBIT Ratio | 14.50 | 11.04 | 12.87 | 14.24 | 10.70 | 17.15 |
EV/FCF Ratio | 7.78 | 6.51 | 10.56 | 31.11 | 5.92 | 5.56 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.24 | 0.24 | 0.29 | 0.30 | 0.25 | 0.30 |
Debt / EBITDA Ratio | 1.21 | 1.14 | 1.39 | 1.55 | 1.29 | 1.42 |
Debt / FCF Ratio | 1.40 | 1.45 | 2.72 | 8.25 | 1.55 | 1.65 |
Net Debt / Equity Ratio | -0.06 | -0.14 | -0.17 | -0.17 | -0.23 | -0.01 |
Net Debt / EBITDA Ratio | -0.38 | -0.81 | -1.00 | -0.86 | -1.20 | -0.08 |
Net Debt / FCF Ratio | -0.36 | -0.85 | -1.61 | -4.53 | -1.42 | -0.07 |
Asset Turnover | 0.86 | 0.81 | 0.77 | 0.72 | 0.79 | 0.68 |
Inventory Turnover | 82.46 | 124.45 | 238.64 | 167.10 | 100.25 | 109.78 |
Quick Ratio | 1.59 | 1.74 | 2.18 | 2.23 | 2.24 | 1.93 |
Current Ratio | 1.66 | 1.78 | 2.21 | 2.26 | 2.27 | 1.99 |
Return on Equity (ROE) | 12.00% | 9.36% | 7.19% | 6.14% | 7.51% | 5.98% |
Return on Assets (ROA) | 3.58% | 3.82% | 3.28% | 2.94% | 3.58% | 2.16% |
Return on Invested Capital (ROIC) | 8.37% | 9.73% | 8.43% | 7.71% | 8.70% | 4.30% |
Return on Capital Employed (ROCE) | 7.80% | 8.20% | 6.90% | 6.30% | 7.40% | 4.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 18, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 8.41% | 7.71% | 5.76% | 5.01% | 6.44% | 7.64% |
FCF Yield | 12.61% | 14.13% | 8.62% | 2.94% | 14.89% | 25.70% |
Dividend Yield | 4.96% | 6.06% | 4.73% | 4.50% | 5.06% | 3.37% |
Payout Ratio | 58.28% | 54.43% | 67.24% | 77.98% | 32.90% | 29.07% |
Buyback Yield / Dilution | -0.84% | -0.12% | -0.07% | -0.17% | -33.03% | -0.22% |
Total Shareholder Return | 3.91% | 5.94% | 4.65% | 4.33% | -27.97% | 3.15% |